TECVAYLI – Prior and Subsequent Antimyeloma Therapy in the MajesTEC-9 Study

SUMMARY  

• Johnson & Johnson does not recommend the use of TECVAYLI in a manner inconsistent with the approved labeling.
• MajesTEC-9 is an ongoing, phase 3, randomized, open-label, multicenter study comparing TECVAYLI with investigator’s choice of pomalidomide, bortezomib and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) who previously received 1-3 prior lines of  therapy (LOTs) including an anti-CD38 monoclonal antibody (mAb) and lenalidomide.¹  
  • Details pertaining to prior antimyeloma therapies, refractory status, and subsequent antimyeloma therapies from the MajesTEC-9 study are summarized below.^1-3  

CLINICAL DATA - MajesTEC-9 STUDY

MajesTEC-9 (NCT05572515) is an ongoing, phase 3, randomized, open-label, multicenter study comparing TECVAYLI with investigator’s choice of PVd or Kd in patients with RRMM who previously received 1-3 prior LOTs including an anti-CD38 mAb and lenalidomide.¹ 

MajesTEC-9 Study – Prior Antimyeloma Therapies

• In the intention to treat (ITT) population, patients had received a median of 2 prior LOT, with 21.6% having received 1 prior LOT and 78.4% having received 2 to 3 prior LOT.² 
• Details pertaining to prior antimyeloma therapy from the MajesTEC-9 study are summarized in Table: MajesTEC-9 Study - Summary of Prior Antimyeloma Therapies (ITT Population).

MajesTEC-9 Study – Refractory Status

• Overall, 92.2% of patients were refractory to their last LOT.¹ 
• Details pertaining to refractory status from the MajesTEC-9 study are summarized in Table: MajesTEC-9 Study – Refractory Status (ITT Population).

MajesTEC-9 Study – Subsequent Antimyeloma Therapies

• Overall, 38.4% of patients received subsequent antimyeloma therapy.² 
• Fewer patients in the TECVAYLI arm received ≥1 subsequent antimyeloma therapy compared with the PVd/Kd arm (18.2% vs 58.6%).³
• Use of antineoplastic agents was lower with TECVAYLI than with PVd/Kd (17.2% vs 56.2%).³
  • Among other antineoplastic agents, the most common subsequent therapies were:
    • TECVAYLI arm: carfilzomib (8.4%), bortezomib (6.4%), selinexor (2.4%), and cisplatin (2.4%)
    • PVd/Kd arm: carfilzomib (6.4%), bortezomib (6.1%), selinexor (4.4%), and cisplatin (3.7%)
  • Among monoclonal antibodies and antibody-drug conjugates, use was lower in the TECVAYLI arm than in the PVd/Kd arm (5.4% vs 42.4%), with the most common subsequent therapies being:
    • TECVAYLI arm: daratumumab (2.4%), teclistamab (0.7%), talquetamab (0.7%), and elotuzumab (0.7%)
    • PVd/Kd arm: teclistamab (18.5%), elranatamab (7.7%), talquetamab (5.4%), and daratumumab (3.7%)
  • Other subsequent therapy classes reported for TECVAYLI vs PVd/Kd included:
    • Alkylating agents: 7.4% vs 13.1%
    • Cytotoxic antibiotics and related substances: 2.7% vs 3.7%
    • Antimetabolites: 0.3% vs 3.4%
    • Corticosteroids for systemic use: 15.2% vs 27.3%
    • Immunosuppressants: 8.8% vs 16.2%

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 01 June 2026.